Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A new paper by a multi-center research team has refined the long-held suspicion that some types of aggressive prostate cancer may be the consequence of the accumulation of multiple mutations in the patients’ DNA.
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, fusion, gene, risk | Leave a Comment »
According to a media release from the Prostate Cancer Foundation yesterday, research at the University of Michigan Comprehensive Cancer Center suggests that the RAF oncogene that drives fatal forms of melanoma (an aggressive type of skin cancer) may also drive aggressive forms of prostate cancer.
Filed under: Diagnosis, Drugs in development, Risk, Uncategorized | Tagged: fusion, gene, oncogene, RAF | 5 Comments »
An article in today’s Israel Herald might give you the (incorrect) idea that androgen deprivation therapy is completely inappropriate as a form of treatment for prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: development, fusion, gene | 1 Comment »
We have long cautioned about whether the presence of apparent biologic “markers” in men with prostate cancer (“association”) is necessarily an implication that a specific marker really indicates anything clinically important. A paper published by a European team now helps to put this in perspective.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: association, fusion, gene, marker, TMPRSS2-ERG | 5 Comments »
In today’s news reports we include items on: ETS gene fusions and their future in the diagnosis and management of prostate cancer Outcomes after different types of radiotherapy Micro-RNAs and late stage prostate cancer
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ETS, fusion, gene, micro RNA, outcome, radiation, therapy | Leave a Comment »
Recent publications reported on today include: Demonstration of the validity of the Epstein criteria in defining pathologically insignificant prostate cancer A review of the value of sildenafil (Viagra) and similar products in treatment of erectile dysfunction among prostate cancer patients A review of the significance of “gene fusion” and its relevance in prostate cancer
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cancer, criteria, Epstein, fusion, gene, inhibitors, insignificant, news, PDE5, prostate, update | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site